June 8, 2018
On 6 June 2018, without news from the U.S. FDA, a press release from Frontier Biotech announced the approval of a new HIV drug in China that is given by once-weekly injection.1
This is a rare example of an HIV treatment not being first approved in either the U.S. or Europe. Albuvitide is an HIV fusion inhibitor that works at an early stage of the HIV lifecycle by blocking attachment to CD4 cells. It has a similar structure and mechanism to an earlier HIV fusion inhibitor called enfuvirtide (T-20, Fuzeon) that was developed for people who had run out of treatment options.
Enfuvirtide was approved in 2003 but has been very rarely for the last ten years used because later drugs have become more effective and have an easier safety profile than the twice-daily subcutaneous injections it required.
These reported good efficacy compared to the second-line treatment option that is currently available in China, an older protease inhibitor lopinavir/r. HIV positive people in China do not have access to integrase inhibitors that are now routinely recommended as first-line treatment in the U.S. and Europe, and that also overcome drug resistance to many other widely used HIV drugs.
From a safety persepective, albuvirtide was also not associated with the injection site reactions that limited the use of enfuvirtide.
Unfortunately the press release on approval in China still only refers to interim results from these studies.
Albuvirtide injection are marketed by Frontier Biotech with the trade name Aikening. There are plans to extend access outside of China, although further details have not been publicised.
In July 2017, the company announced a licensing agreement with with Rockerfeller University in the U.S. to coformulated albuvirtide with the broad neuralising monoclonal antibody 3BNC117.
|Is the World Ready for Long-Acting HIV Treatment?|
|Novel Drugs in the Pipeline for HIV Treatment|
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.